Wednesday's close is the market's freshest read: the S&P 500 rose 0.22% and the Nasdaq gained 0.16%, ending a three-day losing streak, after the Treasury said it would increase buybacks of long-dated debt, pulling the 30-year yield down to 5.19% from Tuesday's 5.28% close. Gold jumped 3.8% and silver 4.5% as the lower-yield backdrop revived the safe-haven bid, while SMH fell another 1.6% even as the broader market rallied. Moderna surged 177% after a Merck-partnered melanoma vaccine hit its Phase 3 goal. U.S. government debt passed $40 trillion for the first time, and Target's earnings beat added to a mixed retail picture ahead of Walmart's report Thursday morning.
The broad market rebounded Wednesday after the Treasury's buyback announcement calmed bond yields — the S&P 500 rose 0.22% and the Nasdaq gained 0.16%, ending a three-day slide. SMH didn't participate: it fell another 1.55%, a divergence MarketWatch frames as a speed bump rather than a trend break, citing past dip-buying opportunities after similar pullbacks.
Nvidia doesn't report until Aug 26. Wednesday's split tape — SPY up, SMH down — leaves the chip trade's next real signal six trading days out, with the buyback-driven yield relief doing more for the broad market than for AI-linked names specifically.
The Treasury said Wednesday it would increase buybacks of longer-dated debt, and the 30-year yield fell to 5.19% from Tuesday's 5.28% close — a reversal WSJ ties directly to Bessent's long-running focus on capping borrowing costs. Gold jumped 3.84% and silver 4.47% as the lower-yield backdrop revived the safe-haven trade CNBC says now sits under fresh pressure from Trump's Fed criticism.
The yen strengthened to ¥158.28 Thursday morning, down 0.82% from Wednesday's close, moving further from ¥160 as U.S. yields retreated. Trump renewed his criticism of Fed policy Wednesday, calling the current rate system "unfair" while still praising Warsh personally — a split signal ahead of this week's FOMC minutes.
Wednesday's Treasury buyback news buys the market some room, but this week's FOMC minutes are still outstanding, Walmart reports Thursday morning, and Nvidia's Aug 26 report remains the next major single-stock catalyst for the AI trade.
Wednesday's dominant single-stock story dwarfed everything else: Moderna gained 176.97% on positive Phase 3 melanoma-vaccine data shared with Merck. On the losing side, La-Z-Boy fell 16.95% on a Q1 earnings miss and weak guidance, while Bally's continued sliding on a going-concern warning disclosed Friday. Today's tofu-agent batch (six sector-level files: big-banks, cybersecurity, enterprise-software, ev-energy, streaming-media, travel-leisure) contained no tickers at all — every name below was sourced independently from FMP price and news data.
Wednesday's reversal came from Bessent's Treasury, not Warsh's Fed: a buyback announcement did what markets had been waiting on FOMC minutes to deliver. Gold's snap-back and SMH's continued weakness show the rally wasn't a uniform risk-on move.
Moderna's 177% surge was the day's biggest single move but sits outside this chain entirely — a company-specific biotech catalyst, not a macro one, and a reminder not every big move belongs to the same story.
Equities: SPY (+0.21%) and QQQ (−0.20%) diverged slightly Wednesday as the S&P ended a three-day slide. SMH (−1.55%) kept falling despite the broader rally, down 4.58% week-to-date — the market's clearest current divergence.
Commodities & rates: the 30-year Treasury yield fell to 5.19% from Tuesday's 5.28% close after Treasury increased long-bond buybacks. Gold (+3.84%) and silver (+4.47%) both jumped on the lower-yield backdrop, while oil (+0.19%) held roughly flat near its recent high.
FX: the yen strengthened to ¥158.28 Thursday morning as U.S. yields retreated. This week's FOMC minutes are still due, though Wednesday's buyback news already answered part of the question markets had been waiting on them for.
The wildcard: whether Wednesday's relief was a genuine turn or a one-day patch on a structural debt story that crossed $40 trillion the same day. Moderna's 177% biotech surge is a reminder that not every big move this week traces back to rates.